{"id":671855,"date":"2023-10-11T16:42:01","date_gmt":"2023-10-11T16:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=671855"},"modified":"2023-10-11T16:42:01","modified_gmt":"2023-10-11T16:42:01","slug":"lag3next-generation-immunotherapy-market-to-showcase-robust-growth-in-the-upcoming-years-asserts-delveinsight-companies-macrogenics-zai-lab-novartis-bristolmyers-squibb-ono-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lag3next-generation-immunotherapy-market-to-showcase-robust-growth-in-the-upcoming-years-asserts-delveinsight-companies-macrogenics-zai-lab-novartis-bristolmyers-squibb-ono-pharmaceuticals_671855.html","title":{"rendered":"LAG-3-Next Generation Immunotherapy Market to Showcase Robust Growth in the Upcoming Years, asserts DelveInsight | Companies – MacroGenics, Zai Lab, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals"},"content":{"rendered":"
\n
\"LAG-3-Next<\/a><\/div>\n
\n
LAG-3-Next Generation Immunotherapy Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018LAG-3-Next Generation Immunotherapy\u2014Competitive Landscape and Market Forecast\u20132035\u2019 report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n

DelveInsight’s ‘LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035<\/strong><\/a>’ report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

The report provides the upcoming drugs, market share of this target by indications, forecasted market size of LAG-3-Next Generation Immunotherapy from 2023 to 2035 segmented by seven major markets. This report discusses the recent findings on LAG-3, the role it plays in regulating immune responses in different cell types and the rationale for targeting LAG-3 for effective cancer immunotherapy. The report also covers the current scenario, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n

Find a sample copy of the LAG-3-Next Generation Immunotherapy Market report @ https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/a>
<\/strong><\/p>\n

LAG-3-Next Generation Immunotherapy Overview<\/strong><\/p>\n

Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 have achieved durable responses in melanoma, renal cancer, Hodgkin’s diseases and lung cancer. However, the success rate of these treatments has been low and a large number of cancers, including colorectal cancer remain largely refractory to CTLA-4 and PD-1 blockade.<\/p>\n

Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. T cells are a type of white blood cell that are part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1. It acts by regulating CD8+ Tcell expansion in immune reactions that have already been initiated (inhibitory signal) and also, by increasing the Treg cell activity.<\/p>\n

Read more about the operations & working of LAG-3-Next Generation Immunotherapy @ https:\/\/www.delveinsight.com\/sample-request\/lag-3-next-generation-immunotherapy-competitive-landscape<\/a>
<\/strong><\/p>\n

Lag-3-Next Generation Immunotherapy Emerging Drugs and Key Companies<\/strong><\/a><\/p>\n

1. MGD013: MacroGenics<\/p>\n

2. LAG525: Novartis<\/p>\n

3. Relatlimab (BMS-986016): Bristol-Myers Squibb<\/p>\n

4. Eftilagimod Alpha (IMP321): Immutep<\/p>\n

5. MK-4280: Merck<\/p>\n

Lag-3-Next Generation Immunotherapy Market <\/strong><\/p>\n

The LAG-3-Next Generation Immunotherapy market outlook helps to cultivate a detailed comprehension of the historical, current and forecasted market trends by analyzing the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n

This segment gives a thorough detail of LAG-3-Next Generation Immunotherapy market trend of each late-stage pipeline therapy by evaluating their impact based on the annual cost of treatment, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear picture of the market at first sight.<\/p>\n

According to DelveInsight, the LAG-3-Next Generation Immunotherapy market is expected to generate USD 7,009 Million in the year 2035 with a significant CAGR in the forecast period (2023\u25002035).<\/strong><\/em><\/p>\n

Interested in knowing how the Lag-3-Next Generation Immunotherapy Market will be growing by 2026? Click to get a snapshot: <\/p>\n

Lag-3-Next Generation Immunotherapy Companies<\/strong><\/a><\/p>\n

Some of the key  Lag-3-Next Generation Immunotherapy companies operating in the  Lag-3-Next Generation Immunotherapy market include MacroGenics, Zai Lab, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, Regeneron, F-star Therapeutics, Xencor, and others.<\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary<\/p>\n

3. Competitive Intensity of LAG-3-Next Generation Immunotherapy<\/p>\n

4. Market Competition of LAG-3-Next Generation Immunotherapy<\/p>\n

5. Technological innovations in LAG-3-Next Generation Immunotherapy<\/p>\n

6. Multivariate analysis of the key players in LAG-3-Next Generation Immunotherapy<\/p>\n

7. LAG-3-Next Generation Immunotherapy Market Overview at a Glance<\/p>\n

8. Pipeline Therapeutics Analysis (Active Products)<\/p>\n

9. Overview: Next Generation Immunotherapy<\/p>\n

10. Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy<\/p>\n

11. SWOT Analysis<\/p>\n

12. Epidemiology and Forecasting Assumptions<\/p>\n

13. Emerging Drugs<\/p>\n

14. Assessment by Indication<\/p>\n

15. Assessment by Route of Administration<\/p>\n

16. Assessment by Stage and Indication<\/p>\n

17. Assessment by stage and Route of Administration<\/p>\n

18. LAG-3-7 Major Market Analysis<\/p>\n

19. Market Drivers<\/p>\n

20. Market Barriers<\/p>\n

21. Appendix<\/p>\n

22. DelveInsight Capabilities<\/p>\n

23. Disclaimer<\/p>\n

24. About DelveInsight<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +91-9650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

LAG-3-Next Generation Immunotherapy Market DelveInsight\u2019s \u2018LAG-3-Next Generation Immunotherapy\u2014Competitive Landscape and Market Forecast\u20132035\u2019 report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-671855","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=671855"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/671855\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=671855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=671855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=671855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}